Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Charles Coombes, MD, PhD, Imperial College London, London, UK, discusses samuraciclib, a first-in-class, oral, selective inhibitor of CDK7, which was evaluated in combination with fulvestrant in patients with advanced hormone receptor-positive HER2-negative breast cancer. This interview took place at the San Antonio Breast Cancer Symposium 2021 in San Antonio.